Clinical Laserthermia Systems announces research collaboration with NIH CC to Study MRI/Ultrasound Fusion-Guided FLA of Prostate Tissue and Prostate Cancer
Lund, Sweden – Clinical Laserthermia Systems AB (publ) (“CLS” or “the Company”) and the US National Institutes of Health Clinical Center ("NIH CC") have initiated a research collaboration regarding MRI/Ultrasound fusion-guided FLA of prostate tissue and prostate cancer.
The collaboration means that NIH CC will start to use and evaluate the TRANBERG® Thermal Therapy System, CLS’s product for the treatment of prostate cancer in male patients.
Prostate cancer is one of the most common forms of cancer, and in the US, over one million prostate biopsies are performed every year leading to a diagnosis of prostate cancer for almost 250,000 men. Focal laser ablation of prostate tumors has demonstrated high levels of precision and accuracy with low risk of side effects, such as erectile dysfunction and urinary incontinence.
“CLS is honored to initiate this collaboration with the NIH to evaluate our TRANBERG laser for image-guided, focal therapies to treat prostate cancer,” said Michael Magnani, President of CLS Americas. “We view this as a strategic relationship and share a common goal with the NIH to effectively treat prostate cancer while also preserving a high quality of life for the patient.”
“We see great potential in the US market and therefore this is a significant partnership that we are very excited to initiate. Together with the NIH, we will be able to gather valuable insights and create better conditions for people affected by prostate cancer," says Dan J Mogren, CEO Clinical Laserthermia Systems AB.
About the National Institutes of Health (NIH)
NIH, US medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.
The information was submitted for publication, through the agency of the contact person set out below on April 13, 2023.
For more information, please contact:
Dan J. Mogren, CEO, Clinical Laserthermia Systems AB (publ)
Phone: +46 (0) 70-590 11 40
E-mail: dan.mogren@clinicallaser.com
About CLS
Clinical Laserthermia Systems AB (publ) develops and sells the TRANBERG®|Thermal Therapy Systems, including Thermoguide Workstation and sterile disposables, for minimally invasive treatment of cancer tumors and drug-resistant epilepsy, according to regulatory approvals in the EU and the US. The products are marketed for image-guided laser ablation and used in studies for treatment with imILT®, the Company's interstitial laser thermotherapy for immunostimulant ablation with potential abscopal effects. CLS is headquartered in Lund and has subsidiaries in Germany, the US and Singapore. CLS is listed on the Nasdaq First North Growth Market under the symbol CLS B. The Certified Advisor (CA) is FNCA Sweden AB, Tel: +46 8 528 00 399. E-mail: info@fnca.se.
For more information about CLS, please visit the Company's website: clinicallaser.se